Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.41 |
| ▸ | HTR6 | P50406 | 6/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.37 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.32 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1431047 | 0.83 | HTR6 (0.42) | PIK3C3HTR6CYP17A1 | |
| SCHEMBL470194 | 0.82 | PIK3C3 (0.38) | PIK3C3HTR6PTGDR2SRCBRD4 | |
| SCHEMBL1251639 | 0.80 | IKBKB (0.51) | PIK3C3HTR6 | |
| SCHEMBL3414679 | 0.79 | PTGDR2 (0.43) | PIK3C3HTR6PTGDR2SRCBRD4 | |
| SCHEMBL13505139 | 0.77 | PTGDR2 (0.46) | PIK3C3HTR6PTGDR2SRCNOD1 | |
| SCHEMBL12450255 | 0.75 | HTR6 (0.45) | HTR6CXCL8NOD1KMT2AMAPT | |
| SCHEMBL1252454 | 0.74 | HTR6 (0.40) | HTR6BRD4CXCL8NOD1KMT2A | |
| SCHEMBL459027 | 0.73 | HTR6 (0.41) | HTR6 | |
| SCHEMBL30134962 | 0.73 | PTGDR2 (0.42) | PIK3C3HTR6PTGDR2CYP17A1SRC | |
| SCHEMBL3413045 | 0.73 | PIK3C3 (0.44) | PIK3C3HTR6PTGDR2SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9326987-B2 | Indazole derivatives for use in the treatment of influenza virus infection | GLAXO GROUP LIMITED (GB) | 2016-05-03 | — | — | US | disclosed |
| US-9326987-B2 | Indazole derivatives for use in the treatment of influenza virus infection | GLAXO GROUP LIMITED (GB) | 2016-05-03 | — | — | US | disclosed |
| US-9326987-B2 | Indazole derivatives for use in the treatment of influenza virus infection | GLAXO GROUP LIMITED (GB) | 2016-05-03 | — | — | US | disclosed |
| US-20130165433-A1 | Novel Use | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-06-27 | — | — | US | disclosed |
| US-20130165433-A1 | Novel Use | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-06-27 | — | — | US | disclosed |
| US-20130165433-A1 | Novel Use | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-06-27 | — | — | US | disclosed |
| US-20120238559-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-09-20 | — | — | US | disclosed |
| US-20120238559-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-09-20 | — | — | US | disclosed |
| US-20120238559-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-09-20 | — | — | US | disclosed |
| WO-2012032065-A1 | INDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF INFLUENZA VIRUS INFECTION | GLAXO GROUP LIMITED (GB) | 2012-03-15 | — | — | WO | disclosed |
| WO-2011067364-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2011-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165433-A1 | Novel Use | HAVCR2, MAVS, ENTPD5 | PIK3C3 4369/4885HTR6 1564/4885PTGDR2 2202/4885 |
| US-20120238559-A1 | NOVEL COMPOUNDS | PIK3CA, PIK3CD, PIK3C2B | PIK3C3 16/4885HTR6 4401/4885PTGDR2 2876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.